|Description||Linsitinib, also known as OSI-906, is an orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGFR-1 stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.|
|Appearance||white solid powder|
|Synonyms||OSI-906; OSI906; OSI 906.|
|Current Developer||OSI Pharmaceuticals, Inc.|
BMS695735 is a benzimidazole inhibitor of the insulin-like growth factor-1 receptor. It was also found to have potent CYP3A4 inhibition. It has broad spectrum i...
Linsitinib, also known as OSI-906, is an orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential anti...
Picropodophyllin, also known as Picropodophyllotoxin, AXL1717 or PPP, is a cyclolignan alkaloid found in the mayapple plant family (Podophyllum peltatum), and a...
BMS-754807 is an orally bioavailable antagonist of human insulin-like growth factor type I receptor (IGF-1R) with potential antineoplastic activity. BMS-7548077...
AG-1024 is also called Tyrphostin, is a selective inhibitor of IGF-1R. AG-1024 was used to evaluate effects on proliferation, radiosensitivity, and radiation-in...
PQ 401 is an IGF-1R inhibitor and inhibits autophosphorylation of the IGF-IR kinase domain at concentrations <100 nM, with an IC50 <1μM.
Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
NVP-ADW742 is a novel small weight molecular inhibitor of IGF-IR with potential anticancer activity. NVP-ADW742 inhibited IGF-IR-mediated proliferation with an...
AEW541, also known as NVP-AEW541, is a novel, potent IGF-IR kinase inhibitor. NVP-AEW541 is capable of distinguishing between the IGF-IR (IC50 = 0.086 microM...
BMS-536924 is a potent small molecule inhibitor of IGF-IR, which shows antitumor activity in multiple tumor models, including sarcoma.
GSK-1904529A is an IGF-1R Inhibitor, is is a promising candidate for therapeutic use in IGF-IR–dependent tumors. GSK1904529A selectively inhibits IGF-IR and I...